Heart failure and diabetes: Time to pay attention

Study drug Trial acronym Target enrollment (n) Population studied Primary composite outcome HF reported as secondary outcome DPP-IV inhibitors Saxagliptin SAVOR-TIMI 53 16,500 Age >=40 y + established CV disease and/or multiple risk factors CV death, nonfatal MI, or nonfatal ischemic stroke Yes Sitagliptin TECOS 14000 Age >=50 y + preexisting CV disease CV death, nonfatal MI, nonfatal stroke, or unstable angina Yes Aloglipliptin EXAMINE 5400 Age >=18 y + ACS CV death, nonfatal MI, or nonfatal stroke No Linagliptin CAROLINA 6000 Age 40-85 y + established CV disease or diabetes end-organ damage or multiple CV risk factors CV death, nonfatal MI, nonfatal stroke, and unstable angina No GLP-1 receptor agonists Exenatide (once weekly) EXSCEL 9500 Age >=18 y + any level of CV risk (CV disease in 60%) CV death, nonfatal MI, or nonfatal stroke Yes Liraglutide LEADER 8754 Age >=50 y + established CV disease or chronic renal failure or chronic HF OR age >=60 y + CV risk factors CV death, nonfatal MI, or nonfatal stroke Yes Lixisenatide ELIXA 6000 Age >=30 y + ACS CV death, nonfatal MI, nonfatal stroke, or unstable angina Yes Dulaglutide REWIND 9622 Age >=50 y + established CV disease or age >=55 y + subclinical vascular disease or age >=60 y + multiple CV risk factors CV death, nonfatal MI, or nonfatal stroke Yes SGLT2 inhibitors Canagliflozin CANVAS 4331 Age >=30 y + established or a high risk for CV disease CV death, nonfatal MI, and nonfatal stroke No BI 10773  4000 Age >18 y + history of either previous MI, unstable angina, multivessel PCI or CABG, stroke, or peripheral occlusive arterial disease CV death, nonfatal MI, and nonfatal stroke No Combined PPAR [alpha]/γ agonist Aleglitazar  6000 Age >18 y + ACS CV death, nonfatal MI, and nonfatal stroke ?